Shopping Cart
- Remove All
Your shopping cart is currently empty
Rifaximin is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 200 mg | $31 | In Stock | |
| 500 mg | $53 | In Stock | |
| 1 g | $81 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $57 | In Stock |
| Description | Rifaximin is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. |
| In vitro | Rifaximin exhibits broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative microorganisms.Rifaximin exhibits a low MIC against Gram-positive bacteria, with a dose range of 0.01 μg/mL to 0.5 μg/mL for MIC 90.Rifaximin binds to the β-subunit of the bacterial DNA-dependent RNA polymerase and inhibits the start of the chain of RNA synthesis. Rifaximin inhibits LPS-induced cytokine and chemokine expression by inhibiting NF-κB DNA binding activity.50 μM Rifaximin reduces changes in pro-inflammatory factor production induced by LPS stimulation in the IEC, such as TNF-α, IL-8, Rantes, and PGE2 in normal intestinal epithelial cells.100 μM Rifaximin is also shown to inhibit LPS-induced cytokine expression by inhibiting NF-κB DNA binding activity. μM Rifaximin effectively reduced the expression of TNFα, IL-8, MIP-3α and RANTES by lipopolysaccharide-induced stimulation. |
| In vivo | Rifaximin exhibits broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative microorganisms.Rifaximin exhibits a low MIC against Gram-positive bacteria, with a dose range of 0.01 μg/mL to 0.5 μg/mL for MIC 90.Rifaximin binds to the β-subunit of the bacterial DNA-dependent RNA polymerase and inhibits the start of the chain of RNA synthesis. Rifaximin inhibits LPS-induced cytokine and chemokine expression by inhibiting NF-κB DNA binding activity.50 μM Rifaximin reduces changes in pro-inflammatory factor production induced by LPS stimulation in the IEC, such as TNF-α, IL-8, Rantes, and PGE2 in normal intestinal epithelial cells.100 μM Rifaximin is also shown to inhibit LPS-induced cytokine expression by inhibiting NF-κB DNA binding activity. μM Rifaximin effectively reduced the expression of TNFα, IL-8, MIP-3α and RANTES by lipopolysaccharide-induced stimulation. |
| Molecular Weight | 785.88 |
| Formula | C43H51N3O11 |
| Cas No. | 80621-81-4 |
| Smiles | COC1\C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=C2N=C2C=C(C)C=CN12 |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (63.62 mM), Sonication is recommended. Ethanol: 3 mg/mL (3.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.